Yet others focus on testing that is widely considered to lack clinical utility (APOE testing to assess Alzheimer risk) [41] and in one of the studies, breast cancer interventions achieved only limited success in reducing interest in genetic testing among lower-risk women for whom genetic testing was not recommended [29]. The gene discussed is APOE; the disease is breast cancer.